Proxy Votes Now

Home › Funds › First Trust › First Trust Nasdaq Pharmaceuticals ETF

First Trust Nasdaq Pharmaceuticals ETF (FTXH) proxy voting record 2025-2026

Fund family: First Trust · Filed by FIRST TRUST EXCHANGE-TRADED FUND VI (CIK 1552740) · SEC series S000053945

Ticker: FTXH (C000169747)

“With management” counts the items where the fund’s own filing gives management’s recommendation (FOR or AGAINST): 476 with, 16 against, 0 abstentions (not counted as with management). Shareholder proposals: 5 FOR, 11 AGAINST, 0 abstained, by the filing’s own vote-source field.

Compared with First Trust as a whole

The same two figures as First Trust’s manager page (194,032 ballot items across 186 funds and accounts), counted the same way for this fund.

2025-2026This fundItemsFirst TrustItems
Voted FOR the board's own proposals (directors, pay, auditor, capital, transactions, fund matters)90.7%47192.8%162,371
Backed environmental and social shareholder proposals at US companiesn/a61.4%2,714

Where this fund voted differently from most First Trust funds

Each ballot item this fund voted is set against the votes of the other First Trust funds and accounts on the same item (same meeting, same proposal): “most funds” is a strict majority of at least three of them, FOR against AGAINST, WITHHOLD or ABSTAIN, with split votes and items not voted left out. Funds in one family can follow separate voting policies, for example ESG funds, sub-advised funds and funds using pass-through voting.

Voted the same way as most First Trust funds on all 439 items where a comparison was possible.

Votes against management by sector

The same votes as “with management” above, by the sector of the company voted on. 98.2% of this fund’s 492 such votes could be given a sector; the other 9 (1.8%) are at companies without one and are not in the table.

SectorVotesAgainst managementShare
Health Care478163.3%
Industrials500.0%

What it voted on

Ballot items by the category the filing put first; “against management” as above.
Proposal typeItemsAgainst management
Director Elections3450
Say-on-Pay540
Audit-related500
Compensation210
Corporate Governance1410
Capital Structure50
Environment or Climate33
Other Social Issues33
Shareholder Rights and Defenses10

Its largest holdings’ meetings

Position = shares voted × a recent share price, for US-listed shares of companies with a page on this site; an estimate for ranking only.

CompanyMeetingEst. positionItemsAgainst mgmt
Johnson & JohnsonApril 23, 2026$3M151
Merck & Co., Inc.May 26, 2026$3M183
AbbVie Inc.May 8, 2026$2M81
Bristol-Myers Squibb CompanyMay 5, 2026$2M151
Pfizer Inc.April 23, 2026$2M161
Viatris Inc.May 15, 2026$2M150
Eli Lilly and CompanyMay 4, 2026$2M102
Biogen Inc.June 9, 2026$1M120

Notable votes against management

MeetingCompanyProposalFundMgmt
April 23, 2026Johnson & JohnsonIndependent Board Chair Shareholder proposalAgainstFor
May 26, 2026Merck & Co., Inc.Shareholder proposal regarding a report on DEI risks in federal contracting. Shareholder proposalAgainstFor
May 26, 2026Merck & Co., Inc.Shareholder proposal regarding a report on healthcare coverage gaps. Shareholder proposalAgainstFor
May 8, 2026AbbVie Inc.Stockholder Proposal - to Adopt a Policy to Require an Independent Chair Shareholder proposalForAgainst
May 5, 2026Bristol-Myers Squibb CompanyShareholder Proposal on the Adoption of a Board Policy that the Chairperson of the Board be an Independent Director Shareholder proposalAgainstFor
April 23, 2026Pfizer Inc.Adopt an Independent Chair Policy Shareholder proposalAgainstFor
May 4, 2026Eli Lilly and CompanyShareholder proposal to adopt a policy and amend the bylaws to require an independent board chair. Shareholder proposalForAgainst
May 4, 2026Eli Lilly and CompanyShareholder proposal to prepare an annual lobbying report. Shareholder proposalAgainstFor
May 19, 2026Amgen Inc.Stockholder proposal to require an independent board chairman. Shareholder proposalAgainstFor
April 30, 2026Gilead Sciences, Inc.To vote on a stockholder proposal requesting a report on the impact of extended patent exclusivities on patient access, if properly presented at the Annual Meeting. Shareholder proposalAgainstFor
April 30, 2026Gilead Sciences, Inc.To vote on a stockholder proposal requesting a report on the risks of ESG and DEI executive compensation metrics, if properly presented at the Annual Meeting. Shareholder proposalAgainstFor
May 13, 2026Vertex Pharmaceuticals IncorporatedShareholder proposal, if properly presented at the meeting, regarding shareholder right to act by written consent. Shareholder proposalForAgainst

Search this fund’s votes by company

496 ballot items at 50 meetings in 2025-2026. Download all votes (CSV)

Recent notable votes

Recent votes against management’s recommendation at large companies.

About this fund’s record

In the 2025-2026 proxy season, First Trust Nasdaq Pharmaceuticals ETF (FTXH) voted at 50 shareholder meetings of 49 companies, on 496 ballot items in all. Where management made a recommendation, the fund followed it on 96.7% of the items and voted against it 16 times. Its most frequent area of disagreement was corporate governance (10 of its votes against management). It voted on 16 shareholder proposals. It voted FOR the board's own proposals less often than First Trust's funds as a whole (90.7% against 92.8%). It voted the same way as most First Trust funds on every item where a comparison was possible.

About this page

Every figure is derived from the fund’s own Form N-PX filings with the SEC, read item by item: one ballot item is the fund’s vote on one proposal at one meeting, and an item filed twice in the season is counted once. Percentages count items, never shares. A season is published only with at least 250 ballot items at 15 meetings. Built November 18, 2026; the family figures are those of First Trust’s manager page. The interactive database shows the same votes company by company, with every other fund that voted.